In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Denali Therapeutics Inc (NASDAQ: DNLI) was $12.29 for the day, down -9.60% from the previous closing price of $13.60. In other words, the price has decreased by -$9.60 from its previous closing price. On the day, 2.89 million shares were traded. DNLI stock price reached its highest trading level at $13.67 during the session, while it also had its lowest trading level at $12.05.
Ratios:
Our analysis of DNLI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.46 and its Current Ratio is at 8.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.
On January 07, 2025, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $31.Robert W. Baird initiated its Outperform rating on January 07, 2025, with a $31 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 1784692480 and an Enterprise Value of 1006688128.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.58, which has changed by -0.36551368 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -34.28%, while the 200-Day Moving Average is calculated to be -46.89%.
Shares Statistics:
DNLI traded an average of 1.12M shares per day over the past three months and 1391340 shares per day over the past ten days. A total of 142.63M shares are outstanding, with a floating share count of 125.71M. Insiders hold about 13.43% of the company’s shares, while institutions hold 88.04% stake in the company. Shares short for DNLI as of 1741910400 were 10505627 with a Short Ratio of 9.35, compared to 1739491200 on 8685245. Therefore, it implies a Short% of Shares Outstanding of 10505627 and a Short% of Float of 8.450000000000001.
